Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies

Journal of the American Academy of Dermatology

Volumn 50, Issue 5, 2004, Pages 722-733

  Geisse, John ^a   Caro, Ivor ^b   Lindholm, Jane ^c   Golitz, Loren ^d   Stampone, Patti ^e   Owens, Mary ^e  

^a Solano Dermatology Associates   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Dermatopathology Associates   (United States)

^d Dermatopathology Service

^e 3M COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMIQUIMOD; INTERFERON; TOLL LIKE RECEPTOR 7;

ADULT; AGED; ARTICLE; BACKACHE; BASAL CELL CARCINOMA; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; EROSION; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HISTOLOGY; HUMAN; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINUSITIS; SKIN ULCER; T LYMPHOCYTE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 2342473348     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.11.066     Document Type: Article

References (10)

1. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200.
2. Gibson S, Lind J, Riter T, Gleason R, Rogers L, Fuller A, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cellular Immunol 2002;218:74-86.
3. Miller RL, Gerster JF, Owens ML, Slade HB, Toami MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1992;21:1-14.
4. Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox T, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-813.
5. Geisse J, Rich P, Pandya A, Gross K, Andres K, Ginkel A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002;47:390-398.
6. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002-7.
7. Shumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter A, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002;138:1165-1171.
8. Sterry W, Ruzicka T, Herrera E, Takwale A, Bichel J, Andres K, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002;147:1227-1236.
9. Newcomb RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17: 857-872.
10. Newcomb RG. Interval estimation for the differences between dependent proportions: comparison of eleven methods. Stat Med 1998;17:873-890.